Xerosis Treatment Market

The Global Xerosis Treatment Market Industry is poised for substantial growth, with projections indicating a market value of 45.5 USD Billion in 2024 and an anticipated increase to 82.5 USD Billion by 2035. This growth is underpinned by a compound annual growth rate (CAGR) of 5.55% from 2025 to 2035. Such projections reflect the increasing demand for effective xerosis treatments, driven by factors such as rising prevalence, advancements in treatment options, and growing consumer awareness. The market's expansion is indicative of the ongoing commitment to improving skin health and addressing the needs of individuals suffering from xerosis.

The increasing incidence of xerosis globally is a primary driver for the Global Xerosis Treatment Market Industry. Factors such as environmental changes, aging populations, and lifestyle choices contribute to this rise. For instance, dry skin conditions are particularly prevalent among older adults, with studies indicating that nearly 50 percent of individuals over the age of 65 experience xerosis. This growing demographic is expected to drive demand for effective treatments, contributing to the market's projected value of 45.5 USD Billion in 2024 and an anticipated growth to 82.5 USD Billion by 2035.

Regulatory bodies are playing a crucial role in shaping the Global Xerosis Treatment Market Industry by streamlining the approval processes for new treatments. Initiatives aimed at expediting the review of dermatological products are encouraging pharmaceutical companies to invest in research and development. This regulatory support not only facilitates the introduction of innovative treatments but also enhances market competition. As a result, patients benefit from a wider array of effective options for managing xerosis. The positive regulatory environment is likely to contribute to the market's growth trajectory in the coming years.

Innovations in dermatological treatments are significantly influencing the Global Xerosis Treatment Market Industry. The development of new topical agents, including emollients and corticosteroids, has enhanced the efficacy of xerosis management. Furthermore, the introduction of combination therapies that integrate moisturizers with active pharmaceutical ingredients is gaining traction. These advancements not only improve patient outcomes but also expand the treatment landscape, potentially increasing market revenue. As the market evolves, the CAGR of 5.55% from 2025 to 2035 reflects the growing acceptance and utilization of these advanced treatment modalities.

Heightened awareness regarding skin health and xerosis is driving the Global Xerosis Treatment Market Industry. Public health campaigns and educational initiatives by dermatological associations emphasize the importance of skin hydration and proper care. This increased knowledge encourages individuals to seek treatment for xerosis, thereby expanding the patient base. Additionally, healthcare providers are becoming more proactive in diagnosing and managing dry skin conditions, which further supports market growth. As awareness continues to rise, the demand for effective treatment options is likely to increase, contributing to the overall market expansion.

The trend towards natural and organic skincare products is reshaping the Global Xerosis Treatment Market Industry. Consumers are increasingly seeking products that contain natural ingredients, driven by concerns over synthetic chemicals and their potential side effects. This shift is prompting manufacturers to innovate and develop formulations that align with consumer preferences. Products featuring botanical extracts and organic components are gaining popularity, appealing to health-conscious consumers. As this trend continues, it is expected to significantly impact market dynamics, potentially leading to increased sales and a broader range of treatment options.

By region, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. The North American xerosis treatment market, covering Canada and Mexico, is seeing steady growth, driven by the rising demand for non-invasive treatments. Market growth in the region is mainly contributed by the increased incidence of xerosis and other similar conditions like eczema and psoriasis in both the US and Canada. For Instance, according to the National Psoriasis Foundation (US), More than 8 million people in the US are affected by psoriasis.

This increased incidence of skin-related disorders has heightened the demand for effective treatments for dry skin, thereby boosting the market for xerosis treatment products in the region. The growing awareness about skincare, coupled with a significant shift towards self-care and natural remedies, further contributes to the surge in demand for both over the counter and prescription treatments. The availability of various treatment options, including lotions, creams, and medicated ointments, allows consumers to address symptoms of xerosis based on their needs, driving market expansion.

Further, the major countries studied are: The US, Canada, Brazil, Germany, France, the UK, Italy, Spain, China, India, Japan, South Korea, and Australia.

FIGURE 3:  Xerosis Treatment Market , BY REGION, 2024 & 2035 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

The growth of the xerosis treatment market in Europe is driven by the increasing prevalence of skin conditions such as xerosis, eczema, and psoriasis, especially in older populations. The European market is witnessing a rise in demand for both topical and oral treatments, fueled by growing awareness of skin health and the availability of a variety of treatment options. In particular, the, Germany, France, and UK account for a significant share of the market due to their advanced healthcare systems and widespread access to dermatological treatments.

According to the European Academy of Dermatology and Venereology (EADV), at least 50% of people over the age of 65 suffer from xerosis, further fueling the demand for effective skincare solutions.

In the Asia-Pacific (APAC) region, the market for xerosis treatment is growing due to increases in skin disorders, mainly in Japan, China, and India. Increased pollution levels, changing climate patterns, and urbanization contribute to a growing case of xerosis and related skin problems. In addition, the increasing concern about health and skincare is boosting the demand for medical and personal care products. The WHO reports that skin disorders and dry conditions are highly common in various APAC countries; therefore, the region is a significant target market for xerosis treatment solutions.

Moreover, China xerosis treatment market held the largest market share in 2024, and Australia xerosis treatment market is the fastest growing market in the Asia-Pacific region.

The  Xerosis Treatment Market is distinguished by the presence of numerous regional and local players catering to the  Xerosis Treatment Market . The market is distinguished by the existence of both prescription-based medicines and over the counter (OTC) drugs, which cater to a variety of customer needs. Larger companies use their established brand reputation, global distribution networks, and research capacity to maintain dominance, whereas smaller, specialized enterprises concentrate on producing limited, focused solutions with a particular emphasis on natural and organic ingredients.

Competition has increased in response to rising demand for effective treatments, which is being driven by challenges such as aging populations and environmental influences on skin health.

Amgen Inc. (Amgen) is a biotechnology firm that develops, creates, manufactures, and sells modern human therapeutics to treat people with life-threatening diseases. The company discovers, develops, manufactures and delivers innovative medicines aimed at combating some of the world’s most challenging diseases. They focus on areas with high unmet medical needs and leverage their expertise to create solutions that significantly improve patient outcomes and lessen the social and economic impact of illness. The company manufactures both biologics and small molecule drugs. Moreover, in August 2024, Amgen announced that Otezla (apremilast) is now available for pediatric use in the U.S.

Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for treating moderate to severe plaque psoriasis in children and adolescents aged 6 and older, weighing at least 20 kg (44 lb), and who are candidates for phototherapy or systemic therapy.